PE20120858A1 - Composiciones solidas que comprenden acido 5-aminolevulinico - Google Patents

Composiciones solidas que comprenden acido 5-aminolevulinico

Info

Publication number
PE20120858A1
PE20120858A1 PE2011002072A PE2011002072A PE20120858A1 PE 20120858 A1 PE20120858 A1 PE 20120858A1 PE 2011002072 A PE2011002072 A PE 2011002072A PE 2011002072 A PE2011002072 A PE 2011002072A PE 20120858 A1 PE20120858 A1 PE 20120858A1
Authority
PE
Peru
Prior art keywords
aminolevulinic acid
hydrogenated
triglycerides
solid compositions
compositions including
Prior art date
Application number
PE2011002072A
Other languages
English (en)
Spanish (es)
Inventor
Oddveig Sellaeg Helland
Gry Stensrud
Bjorn Klem
Jon Erik Braenden
Aslak Godal
Jo Klaveness
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42628133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120858(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Photocure Asa filed Critical Photocure Asa
Publication of PE20120858A1 publication Critical patent/PE20120858A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/00615-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036Porphyrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2011002072A 2009-06-11 2010-06-11 Composiciones solidas que comprenden acido 5-aminolevulinico PE20120858A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09251538 2009-06-11

Publications (1)

Publication Number Publication Date
PE20120858A1 true PE20120858A1 (es) 2012-08-01

Family

ID=42628133

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002072A PE20120858A1 (es) 2009-06-11 2010-06-11 Composiciones solidas que comprenden acido 5-aminolevulinico

Country Status (18)

Country Link
US (1) US20120134921A1 (enExample)
EP (1) EP2440188A1 (enExample)
JP (1) JP2012529451A (enExample)
KR (1) KR20140014401A (enExample)
CN (1) CN102802612A (enExample)
AU (1) AU2010257752B2 (enExample)
BR (1) BRPI1011650A2 (enExample)
CA (1) CA2763837A1 (enExample)
CL (1) CL2011003115A1 (enExample)
CO (1) CO6480960A2 (enExample)
CR (1) CR20110649A (enExample)
MX (1) MX2011013069A (enExample)
NZ (1) NZ596946A (enExample)
PE (1) PE20120858A1 (enExample)
RU (1) RU2527328C2 (enExample)
SG (1) SG176687A1 (enExample)
WO (1) WO2010142456A1 (enExample)
ZA (1) ZA201108850B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521251A (ja) * 2010-03-01 2013-06-10 フォトキュア エイエスエイ 美容組成物
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
US20140067024A1 (en) 2012-08-30 2014-03-06 Photocure Asa Dual panel photodynamic therapy lamp
GB201221123D0 (en) 2012-11-23 2013-01-09 Photocure As Device for photodynamic treatment
KR20150141958A (ko) * 2013-03-12 2015-12-21 어플라이드 바이오리서치, 인크. 개선된 약물 전달을 위한 킬레이트화 좌제
JP6588193B2 (ja) * 2014-07-31 2019-10-09 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップCapsugel Belgium NV カプセル製剤
US20170216146A1 (en) * 2014-07-31 2017-08-03 Capsugel Belgium Nv Capsule formulation
US11623008B2 (en) * 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
US9956426B2 (en) 2015-02-26 2018-05-01 Amol Punjabi Upconverting nanoparticles
AU2016372575B2 (en) 2015-12-17 2022-12-08 Photocure Asa Method of photodynamic therapy (PDT) for bladder cancer
GB201522398D0 (en) 2015-12-18 2016-02-03 Photocure As Device for photodynamic therapy
CN105481946B (zh) * 2015-12-18 2019-05-21 浙江工商大学 5-氨基酮戊酸与3-羟基吡啶-4-酮的缀合物及其制备法和用途
US10744212B2 (en) 2016-03-14 2020-08-18 General Electric Company Topical application of nerve labeling dyes for image-guided surgery
GB2546128A (en) * 2016-09-28 2017-07-12 Photocure Asa Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
CN107434753A (zh) * 2017-07-26 2017-12-05 南京大学 5‑氨基乙酰丙酸及其衍生物的泡腾片及其制备方法
PH12020550124B1 (en) 2017-12-01 2024-05-24 Nat Ct Child Health & Dev Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3181062B2 (ja) * 1991-01-31 2001-07-03 帝國製薬株式会社 下部消化管崩壊経口製剤
US6492420B2 (en) * 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
CZ291132B6 (cs) * 1995-03-10 2002-12-11 Photocure Asa Estery kyselin 5-aminolevulových a farmaceutický prostředek s jejich obsahem
EP2127642A3 (en) * 1998-08-13 2010-02-24 Cima Labs, Inc. Microemulsions as solid dosage forms for oral administration
EP1184038B1 (en) * 1999-06-09 2005-12-28 Mochida Pharmaceutical Co., Ltd. System for release in lower digestive tract
DE10003620A1 (de) * 2000-01-28 2001-08-02 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
GB0018528D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Compounds
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US7264629B2 (en) * 2001-11-09 2007-09-04 Qlt, Inc. Photodynamic therapy for the treatment of hair loss
TW577606U (en) * 2001-11-20 2004-02-21 Carry Computer Eng Co Ltd Improved structure of all-in-one silicon disk
DE102005019628A1 (de) * 2005-04-26 2006-11-09 Technische Universität Braunschweig Formulierung zur dermalen Anwendung
GB0609809D0 (en) * 2006-05-17 2006-06-28 Photocure Asa Product
GB0724279D0 (en) * 2007-12-12 2008-01-23 Photocure Asa Use

Also Published As

Publication number Publication date
US20120134921A1 (en) 2012-05-31
AU2010257752B2 (en) 2015-04-09
ZA201108850B (en) 2013-02-27
RU2011150920A (ru) 2013-07-20
NZ596946A (en) 2014-07-25
EP2440188A1 (en) 2012-04-18
CN102802612A (zh) 2012-11-28
CR20110649A (es) 2012-03-22
RU2527328C2 (ru) 2014-08-27
JP2012529451A (ja) 2012-11-22
AU2010257752A1 (en) 2012-01-12
CO6480960A2 (es) 2012-07-16
WO2010142456A1 (en) 2010-12-16
SG176687A1 (en) 2012-01-30
BRPI1011650A2 (pt) 2016-03-22
CA2763837A1 (en) 2010-12-16
CL2011003115A1 (es) 2012-06-22
MX2011013069A (es) 2012-02-01
KR20140014401A (ko) 2014-02-06

Similar Documents

Publication Publication Date Title
PE20120858A1 (es) Composiciones solidas que comprenden acido 5-aminolevulinico
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
PE20110291A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE20181523A1 (es) Tratamiento de lupus nefritis usando laquinimod
PE20141672A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4�7
PE20150626A1 (es) Modificador del sabor dulce
CL2015001695A1 (es) Una composicion de dos componentes para entregar zinc a un cuerpo comprendiendo (i) un primer componente de un complejo de halogenuro de zinc y (aminoacido o trialquilglicina) y (ii) un segundo componente de cisteina, en donde el primer y segundo componente se mantienen separados uno del otro hasta que se dispensan y se combinan para aplicarse al cuerpo, util para el cuidado oral y personal.
EA201291068A1 (ru) Фотоактивируемые кислород-выделяющие композиции и способы отбеливания зубов
MX380711B (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de accion sistemica, metodos y usos de las mismas.
PE20070977A1 (es) Formulacion farmaceutica que comprende pleconaril
GT201200099A (es) Derivados que contienen antraquinona como productos agricolas bioquimicos
PE20091392A1 (es) Composiciones farmaceuticas como agentes antiinflamatorios
MX2012005013A (es) Pterostilbeno (peter) para su uso en la prevencion y/el tratamiento de enfermedades, daños o lesiones de la piel.
CO6470893A2 (es) Agente y método de control para podredumbre blanda
RU2016135039A (ru) Композиция для обработки поверхностных дефектов
ECSP11011479A (es) Compuestos heterocíclicos de fenoximetilo
UY29526A1 (es) Amidas de rcido pirazolcarboxelico
AR071339A1 (es) Formulacion solida de compuesto activo de baja fusion
MX2011009093A (es) Metodo para disolver agentes antimicoticos, y composiciones con una alta concentracion de agentes antimicoticos, apropiado para su aplicacion a las uñas.
PE20141068A1 (es) Formulaciones topicas de tipo suspension que comprenden depsipeptido ciclico
AR061269A1 (es) Composicion y metodo de revascularizacion para el tratamiento de enfermedades isquemicas usando eritropoyetina
CL2009001366A1 (es) Compuestos derivados de heterociclil-sulfonamidas con un grupo de cabeza de heterociclo y oxadiazolona; composicion farmaceutica y su proceso de preparacion; y su uso para el tratamiento y/o prevencion de trastornos del metabolismo de acidos grasos y de la glucosa, tal como diabetes mellitus, resistencia a la insulina, dislipidemias, entre otras.
PE20091900A1 (es) Una formulacion farmaceutica solida
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.

Legal Events

Date Code Title Description
FC Refusal